Details

Autor(en) / Beteiligte

• Tong, Xin-Yu
• Quan, Yuan
• Zhang, Hong-Yu

Titel

NUDT5 as a novel drug target and prognostic biomarker for ER-positive breast cancer

Ist Teil von

• Drug discovery today, 2021-03, Vol.26 (3), p.620-625

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• •ATP is important in shaping estrogen function by mediating phase separation.•NUDT5 is a key factor in producing ATP in the nucleus of breast cancer cells.•NUDT5 plays an important role in the pathogenesis of breast cancer.•NUDT5 is a novel drug target and prognostic biomarker for ER+breast cancer. Breast cancer (BRCA) is the most common malignant tumor in women. The estrogen receptor-positive (ER+) subtype accounts for ∼70% of BRCA cases. Estrogen is a crucial hormone that directly stimulates the growth and development of mammary glands. Recent studies revealed that, as an estrogen cofactor, ATP has an important role in determining the action of estrogen by mediating phase separation. NUDT5 has been recognized as a key factor for ATP production in the nucleus of BRCA cells and, therefore, could represent a novel drug target for ER+ BRCA. Based on a survival analysis of patients with BRCA documented in The Cancer Genome Atlas (TGCA) database, we show that NUDT5 is also a potential prognostic biomarker for ER+ BRCA.